Briacell Therap (NASDAQ:BCTX) & ANI Pharmaceuticals (NASDAQ:ANIP) Critical Review

ANI Pharmaceuticals (NASDAQ:ANIP) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for ANI Pharmaceuticals and Briacell Therap, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0	3	6	0	2.67
Briacell Therap	1	0	0	0	1.00

ANI Pharmaceuticals presently has a consensus price target of $105.00, suggesting a potential upside of 35.22%. Given ANI Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe ANI Pharmaceuticals is more favorable than Briacell Therap.

Volatility and Risk

ANI Pharmaceuticals has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Briacell Therap has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.

Profitability

This table compares ANI Pharmaceuticals and Briacell Therap’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Briacell Therap	N/A	-153.53%	-129.26%

Valuation and Earnings

This table compares ANI Pharmaceuticals and Briacell Therap”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37 million	2.00	$78.34 million	$3.95	19.66
Briacell Therap	N/A	N/A	-$26.31 million	($7.92)	-0.45

ANI Pharmaceuticals has higher revenue and earnings than Briacell Therap. Briacell Therap is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

76.0% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Briacell Therap shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

ANI Pharmaceuticals beats Briacell Therap on 12 of the 13 factors compared between the two stocks.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.